Is there any metabolic parameter of staging 18F-FDG-PET/CT related to the therapeutic strategy performed (primary cytoreduction vs. neoadjuvant chemotherapy and interval cytoreduction) in patients with high-grade serous ovarian cancer?

被引:0
作者
Sancho Rodriguez, L. [1 ]
Sanchez Lorenzo, L. [1 ]
Boria Alegre, F. [1 ]
Iscar Galan, T. [1 ]
Garcia Belaustegui, L. [1 ]
Carrasco Rubio, V. [1 ]
Beorlegui Arteta, C. [2 ]
Romera Caballo, M. [3 ]
Betech Anta, V. [3 ]
Garcia Velloso, M. [3 ]
机构
[1] Clin Univ Navarra, Madrid, Spain
[2] Dept Salud Gobierno Navarra, Madrid, Spain
[3] Clin Univ Navarra, Pamplona, Spain
关键词
D O I
暂无
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
EP-0706
引用
收藏
页码:S711 / S711
页数:1
相关论文
共 4 条
[1]  
[Anonymous], 2022, J GYNECOL ONCOL, V33, pe28
[2]  
[Anonymous], 2018, EUR J NUCL MED MOL I, V45, P1224
[3]  
[Anonymous], 2020, CANC RES TREAT, V52, P1211
[4]  
[Anonymous], 2020, ANN NUCL MED, V34, P128